Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Fiche publication
Date publication
février 2016
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel
Tous les auteurs :
Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S
Lien Pubmed
Résumé
There is continuing controversy regarding the optimal regimen for neoadjuvant chemotherapy (NAC) in bladder cancer.
Mots clés
Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Chemotherapy, Adjuvant, Cisplatin, administration & dosage, Cystectomy, Doxorubicin, administration & dosage, Drug Administration Schedule, Female, France, Humans, Kaplan-Meier Estimate, Male, Methotrexate, administration & dosage, Middle Aged, Neoadjuvant Therapy, adverse effects, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms, drug therapy, Urothelium, drug effects, Vinblastine, administration & dosage
Référence
Eur. J. Cancer. 2016 Feb;54:69-74